Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin

NCT ID: NCT04253704

Last Updated: 2020-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-13

Study Completion Date

2017-03-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a placebo-controlled double-blinded trial to compare effects of 2% IDL lotion to placebo in female subjects with dry skin. Primary endpoints were skin hydration (NovaMeter) and transepidermal water loss (VapoMeter).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Objective: To evaluate the efficacy of two topically applied test materials and the ability to increase hydration and decrease the transepidermal water loss of the skin. Efficacy was evaluated instrumentally using the NovaMeter and VapoMeter.
2. Test Material Description: On January 4, 2017, two test samples labeled Hydrating Lotion HydraSynol IDL RC-02-38, 12/21/16 and Hydrating Lotion Control RC-02-38A, 12/21/16 were received from Sytheon Ltd. and assigned CR Lab Nos.: P0104-B1 and P0104-B2, respectively.
3. Test Material Handling: Upon arrival at Cantor Research Laboratories, Inc., the test materials were assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received and tests requested. Samples are retained for a period of three months beyond submission of final report unless otherwise specified by the sponsor or if sample is known to be in support of governmental applications, in which case retained samples are kept two years beyond final report submission. Sample disposal is conducted in compliance with appropriate federal, state and local ordinances.
4. Recruitment: Panel selection was accomplished by advertisements in local periodicals, community bulletin boards, phone solicitation, electronic media or any combination thereof.
5. Informed Consent: In compliance with 21 CFR Ch.1 Part 50, Subpart B, informed consent was obtained from each volunteer prior to the commencement of the study. The consent form described the procedures, possible adverse effects, associated risks, and potential benefits of the study and the limits of liability. Panelists signed and dated the informed consent document to indicate their authorization to proceed and acknowledge their understanding of the contents.
6. NovaMeter: The Novameter is a multifunctional electronic laboratory instrument that measures skin impedance. It is designed to provide non-invasive, objective, reproducible method of measurement to quantify biophysical characteristics and relative hydration of the skin.
7. VapoMeter: The VapoMeter is a fully portable instrument for measureing TEWL (transepidermal water loss) values and evaporation rates. TEWL is an indicator of the skin's barrier function. The core of the VapoMeter is a sensitive humidity sensor that is inside a cylindrical measurement chamber. This chamber is closed by the skin or other measurement surface during the measurement period and is unaffected by ambient airflows. The sensor monitors the increase of relative humidity (RH) inside the chamber during the measurement. The evaporation rate value (g/m²h) is automatically calculated from the RH increase. The chamber is passively ventilated between measurements and the ventilation time is automatically controlled. The VapoMeter is widely accepted and an efficient instrument for TEWL measurements.
8. Washout period: Five days prior to the study the panelists were told to not use any moisturizers or treatment products on their arms and refrain from using any other products during the course of the study. They were asked to wash their arms with only ivory soap and pat dry.
9. Baseline: The panelists arrived at the lab with their arms washed by water alone (if forearm skin was not dry, the panelist was asked to wash their arms with only ivory soap and pat dry). Panelists with Skin Dryness Grade of 6 and 7 were inducted in the study. A trained technician examined the test areas (left and right volar arms) for any abnormalities that would obstruct the measurements. The left arm was used for the test material Hydrating Lotion HydraSynol IDL RC-02-38, 12/21/16 (CR Lab No. P0104-B1). The right arm was used for Hydrating Lotion Control RC-02-38A, 12/21/16 (CR Lab No. P0104-B2). The panelists were required to equilibrate to the controlled environment with a constant temperature of 70 degrees F and humidity of 30% Rh for half hour. Measurements on each arm (left and right volar arms) were taken using the NovaMeter and VapoMeter. A trained technician then applied each test material to the respective volar arm in order for the panelist to observe the manner in which the products should be applied for two weeks. The test materials were allowed to dry before the dismissal of the panelist. The panelists were then given the pre weighed test materials as well as a study diary in order to list the time of each application, the date and any subjective comments that they might have about the test materials.
10. Week 2: The panelists arrived at the lab with their arms applied with the test materials at least five hours prior. A trained technician examined the test areas (left and right volar arms) for any abnormalities that would obstruct the measurements. The panelists were allowed to equilibrate to the controlled environment with a constant temperature of 70 degrees F and humidity of 30% Rh for a half hour. Measurements on each arm (left and right volar arms) were taken again using the NovaMeter and VapoMeter. The test materials were weighed and diaries collected to check for compliance.
11. Day 18 (after 4 days regression): The panelists arrived at the lab. A trained technician examined the test areas (left and right volar arms) for any abnormalities that would obstruct the measurements. The panelists were allowed to equilibrate to the controlled environment with a constant temperature of 70 degrees F and humidity of 30% Rh for a half hour. Measurements on each arm (left and right volar arms) were taken again using the NovaMeter and VapoMeter.
12. Adverse reactions: Subjects were instructed to report any delayed reactions which might occur after the final reading. Clients are notified immediately in the case of an adverse reaction and a determination is made as to a treatment program if necessary.
13. Statistical Analysis: All of the data was tabulated in a Microsoft® Excel spreadsheet. Using the t-Test, the statistical significance of the net change from baseline (pre-application) to each subsequent time point was assessed. Statistical significance was defined at the p=0.05 or less level (corresponding to a 95% or greater confidence level).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Xerosis Cutis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Test materials were applied to forearm skin of each subject. The left arm was used for the test material IDL lotion. The right arm was used for the hydrating control lotion.
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors
Participants were not told which arm received treatment versus placebo lotions.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2% IDL lotion

The left arm of each subject was used for the test material hydrating lotion (IDL).

Group Type EXPERIMENTAL

IDL lotion

Intervention Type COMBINATION_PRODUCT

IDL lotion is water-based (\> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).

Control lotion

The right arm of each subject was used for control lotion lacking the IDL component.

Group Type PLACEBO_COMPARATOR

Control lotion

Intervention Type COMBINATION_PRODUCT

Control lotion is water-based (\> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IDL lotion

IDL lotion is water-based (\> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).

Intervention Type COMBINATION_PRODUCT

Control lotion

Control lotion is water-based (\> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).

Intervention Type COMBINATION_PRODUCT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IDL RC-02-38 / P0104-B1 RC-02-38A / P0104-B2

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Females who were thirty-five to fifty-seven years of age.
2. Individuals free of any dermatological or systemic disorder, which would have interfered with the results, at the discretion of the investigator.
3. Individuals who had completed a preliminary medical history mandated by Cantor Research Laboratories, Inc.
4. Individuals who had read, understood and signed an informed consent document as required by Reference 21 CFR Ch. 1 Part 50, Subpart B. Consent forms are kept on file and are available for examination on the premises of Cantor Research Laboratories, Inc., only.
5. Individuals who had abstained from the use of all moisturizing products for at least one week prior to treatment conditions.
6. Individuals with known dry skin.

Exclusion Criteria

1. Individuals who were under doctor's care.
2. Individuals who were taking medication, which in the opinion of the investigator would have masked or interfered with the results.
3. Individuals with chronic skin allergies.
4. Females who were pregnant or lactating.
Minimum Eligible Age

35 Years

Maximum Eligible Age

57 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sytheon Ltd.

INDUSTRY

Sponsor Role collaborator

Shyla Cantor

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shyla Cantor

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shyla Cantor, PhD

Role: STUDY_DIRECTOR

Cantor Research Laboratory

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cantor Research Laboratory

Blauvelt, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.cantorlabs.com/

Cantor Research Laboratory Website

https://www.sytheonltd.com/

Sytheon LTD Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SYT.P0104-B1.B2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RTA 408 Lotion in Healthy Volunteers
NCT02029716 COMPLETED PHASE1